<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00124839</url>
  </required_header>
  <id_info>
    <org_study_id>Naltrexon-BPS</org_study_id>
    <nct_id>NCT00124839</nct_id>
  </id_info>
  <brief_title>Naltrexone in Borderline Personality Disorder</brief_title>
  <official_title>Evaluation of the Efficacy of the Opioid Antagonist Naltrexone on the Incidence and Intensity of Flashbacks and Dissociative States in Patients With Borderline Personality Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Institute of Mental Health, Mannheim</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Institute of Mental Health, Mannheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate whether naltrexone reduces the intensity and
      duration of flashbacks and dissociative states in patients with borderline personality
      disorder.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Difficulties in recruiting enough subjects
  </why_stopped>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of dissociative symptoms</measure>
    <time_frame>End of 3rd week treatment of naltrexon</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction of flashbacks</measure>
    <time_frame>End of 3rd week treatment of naltrexone</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of self-injurious behavior</measure>
    <time_frame>End of 3rd week treatment of naltrexone</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of psychopathology (depression, anxiety, anger, borderline symptoms)</measure>
    <time_frame>End of 3rd week treatment of naltrexone</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety regarding liver enzyme elevation</measure>
    <time_frame>End of 3rd week treatment of naltrexone</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Borderline Personality Disorder</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Blinded sequential administration: naltrexon 50 mg (3 weeks)- placebo (3 weeks)- placebo (1 week)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Blinded sequential administration: 200mg naltrexone (3 weeks) - placebo (3 weeks)- placebo (1 week)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Blinded sequential administration: placebo (3 weeks) - 200mg naltrexone (3 weeks) - placebo (1 week)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Blinded sequential administration: placebo (3 weeks) - 50mg naltrexone (3 weeks) - placebo (1 week)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone</intervention_name>
    <description>Daily oral administration (capsules): 50mg naltrexone and placebo or 200mg naltrexone and placebo or placebo and naltrexon 50mg or placebo and 200mg naltrexone</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  In- and Outpatients:Borderline personality disorder according to the Diagnostic and
             Statistical Manual for Mental Disorders, 4.Edition (DSM IV)

          -  DES-(Dissociative Experience Scale)-score: &gt; or equal 18 according to amendment4
             (former value according to amendment 2 was &gt; or equal 25).

          -  Urinary test of opiates negative

          -  No psychopharmacological treatment for two weeks prior to study (fluoxetine four
             weeks)

          -  No Lithium for two months

        Exclusion Criteria:

          -  Lifetime diagnosis of psychotic disorder

          -  Current major depressive disorder (MDD)

          -  Lifetime diagnosis opioid dependence or current opioid abuse (10 to 7 days prior to
             study)

          -  Comedication with opioid analgetics

          -  Known naltrexone intolerance

          -  Liver disease

          -  Pregnancy and lactation period

          -  Other severe medical or neurological diseases

          -  Simultaneous participation in another study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Bohus, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>University of Heidelberg, Central Institute of Mental Health Mannheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept. of Psychosomatic Medicine, Central Instiute of Mental Health</name>
      <address>
        <city>Mannheim</city>
        <state>Baden-Würtemberg</state>
        <zip>68159</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik Dr. Schlemmer GmbH, Center for Psychosomatic Medicine</name>
      <address>
        <city>Bad Wiessee</city>
        <state>Bavaria</state>
        <zip>83707</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inntalklinik Simbach am Inn</name>
      <address>
        <city>Simbach</city>
        <state>Bavaria</state>
        <zip>84359</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept.of Psychiatry and Psychotherapy; Center of Neurology</name>
      <address>
        <city>Rostock</city>
        <state>Mecklenburg-Vorpommern</state>
        <zip>18147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept.of Psychiatry and Psychotherapy , Rheinische Kliniken Köln</name>
      <address>
        <city>Cologne</city>
        <state>Nordrhein-Westfalen</state>
        <zip>51109</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Schmahl C, Bohus M. [Treatment of dissociative symptoms in borderline personality disorder with naltrexone: supplementary comments]. Nervenarzt. 2000 May;71(5):427. German.</citation>
    <PMID>10846724</PMID>
  </reference>
  <reference>
    <citation>Bohus MJ, Landwehrmeyer GB, Stiglmayr CE, Limberger MF, Böhme R, Schmahl CG. Naltrexone in the treatment of dissociative symptoms in patients with borderline personality disorder: an open-label trial. J Clin Psychiatry. 1999 Sep;60(9):598-603.</citation>
    <PMID>10520978</PMID>
  </reference>
  <reference>
    <citation>Schmahl C, Stiglmayr C, Böhme R, Bohus M. [Treatment of dissociative symptoms in borderline patients with naltrexone]. Nervenarzt. 1999 Mar;70(3):262-4. German.</citation>
    <PMID>10231814</PMID>
  </reference>
  <verification_date>April 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 27, 2005</study_first_submitted>
  <study_first_submitted_qc>July 27, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2005</study_first_posted>
  <last_update_submitted>April 14, 2008</last_update_submitted>
  <last_update_submitted_qc>April 14, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2008</last_update_posted>
  <keyword>Dissociation</keyword>
  <keyword>Flashbacks</keyword>
  <keyword>Self-injurious behavior</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Personality Disorders</mesh_term>
    <mesh_term>Borderline Personality Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

